BACKGROUND: In 2001, the Canadian Psychiatric Association and the Canadian Network for Mood and Anxiety Treatments (CANMAT) partnered to produce evidence-based clinical guidelines for the treatment of depressive disorders. A revision of these guidelines was undertaken by CANMAT in 2008-2009 to reflect advances in the field. There is renewed interest in refined approaches to brain stimulation, particularly for treatment resistant major depressive disorder (MDD). METHODS: The CANMAT guidelines are based on a question-answer format to enhance accessibility to clinicians. An evidence-based format was used with updated systematic reviews of the literature and recommendations were graded according to Level of Evidence using pre-defined criteria. Lines of Treatment were identified based on criteria that included evidence and expert clinical support. This section on "Neurostimulation Therapies" is one of 5 guidelines articles. RESULTS: Among the four forms of neurostimulation reviewed in this section, electroconvulsive therapy (ECT) has the most extensive evidence, spanning seven decades. Repetitive transcranial magnetic (rTMS) and vagus nerve stimulation (VNS) have been approved to treat depressed adults in both Canada and the United States with a much smaller evidence base. There is also emerging evidence that deep brain stimulation (DBS) is effective for otherwise treatment resistant depression, but this is an investigational approach in 2009. LIMITATIONS: Compared to other modalities for the treatment of MDD, the data based is limited by the relatively small numbers of randomized controlled trials (RCTs) and small sample sizes. CONCLUSIONS: There is most evidence to support ECT as a first-line treatment under specific circumstances and rTMS as a second-line treatment. Evidence to support VNS is less robust and DBS remains an investigational treatment.
焦虑症、抑郁症的治疗,目前国内外采用以下药物:l)三环和四环类抗抑郁 剂:三环类:米帕明、地昔帕明、阿米替林、去曱替林、曲米帕明、多塞平 等;四环类:马普替林等。其机理是通过阻断5-HT和NE再摄入各自的神 经末梢,从而发挥其抗抑郁作用。但三环和四环类抗抑郁剂存在的副作用是 1、心血管作用(心跳加速,体位性低血压),2、抗胆碱作用(视力模糊,口干, 窦性心动过速,便秘,尿潴留),3、抗组胺作用(镇静和体重增加)。2)单胺 氧化酶(MAO)抑制剂:非选择性MAO抑制剂:苯乙肼、异卡波肼、反苯环 丙胺;A型MAO抑制剂:吗氯贝胺和溴法罗明。其机理:通过抑制MAO, 提高神经系统内单胺含量,从而发挥其抗抑郁作用。这类药物的副作用是: 导致肝毒性和酪胺高敏感性。3)选择性5-羟色胺重吸收抑制剂(SSRI):药物: 氟西汀、帕罗西汀、舍曲林、氟伏沙明等。机理:通过选择性阻断5-羟色胺 的摄取而发挥作用。副作用:恶心、呕吐或食欲减退。4)非典型抗抑郁药: 5-HT受体拮抗及5-HT重吸收抑制剂曲唑酮,NE及DA重吸收抑制剂安 非他酮和奈法唑酮,5-HT及NE重吸收抑制剂文拉法辛。从上述指出的药 物所存在的缺点:主要是副作用大、疗效不理想、价格昂贵,患者依从性差 而制约了临床应用。
根据目前国内外抑郁症药物治疗指南,一般推荐SSRIs、SNRIs、NaSSAs等新一代抗抑郁症药作为首选药物。在我国部分地区,由于经济限制,TCAs如阿米替林、氯米帕明、麦普替林等仍作为一线治疗药物[9]。抗抑郁症药物具有不同的作用机制及不良反应,对每个人的治疗应答也不尽相同,合理选择与应用药物尤为重要。英国精神药理协会(British Association for Psychopharmacology,BAP)对目前一线抗抑郁症药物治疗疗效进行进一步文献荟萃分析,在其更新的循证医学指南 [11] 中指出,相比于SSRIs,双通道阻断药SNRIs(如文拉法辛)可能具有更高的特异性及更好的疗效;而在SSRIs中,艾司西酞普兰的疗效可能优于其他SSRIs;综合考虑治疗应答率、疗效、耐受性等因素时,选择舍曲林及艾司西酞普兰可能治疗效果最佳。
BACKGROUND: In 2001, the Canadian Psychiatric Association and the Canadian Network for Mood and Anxiety Treatments (CANMAT) partnered to produce evidence-based clinical guidelines for the treatment of depressive disorders. A revision of these guidelines was undertaken by CANMAT in 2008-2009 to reflect advances in the field. There is renewed interest in refined approaches to brain stimulation, particularly for treatment resistant major depressive disorder (MDD). METHODS: The CANMAT guidelines are based on a question-answer format to enhance accessibility to clinicians. An evidence-based format was used with updated systematic reviews of the literature and recommendations were graded according to Level of Evidence using pre-defined criteria. Lines of Treatment were identified based on criteria that included evidence and expert clinical support. This section on "Neurostimulation Therapies" is one of 5 guidelines articles. RESULTS: Among the four forms of neurostimulation reviewed in this section, electroconvulsive therapy (ECT) has the most extensive evidence, spanning seven decades. Repetitive transcranial magnetic (rTMS) and vagus nerve stimulation (VNS) have been approved to treat depressed adults in both Canada and the United States with a much smaller evidence base. There is also emerging evidence that deep brain stimulation (DBS) is effective for otherwise treatment resistant depression, but this is an investigational approach in 2009. LIMITATIONS: Compared to other modalities for the treatment of MDD, the data based is limited by the relatively small numbers of randomized controlled trials (RCTs) and small sample sizes. CONCLUSIONS: There is most evidence to support ECT as a first-line treatment under specific circumstances and rTMS as a second-line treatment. Evidence to support VNS is less robust and DBS remains an investigational treatment.
Abstract DESCRIPTION: Update of the 2009 U.S. Preventive Services Task Force (USPSTF) recommendation on screening for major depressive disorder (MDD) in children and adolescents. METHODS: The USPSTF reviewed the evidence on the benefits and harms of screening; the accuracy of primary care-feasible screening tests; and the benefits and harms of treatment with psychotherapy, medications, and collaborative care models in patients aged 7 to 18 years. POPULATION: This recommendation applies to children and adolescents aged 18 years or younger who do not have a diagnosis of MDD. RECOMMENDATION: The USPSTF recommends screening for MDD in adolescents aged 12 to 18 years. Screening should be implemented with adequate systems in place to ensure accurate diagnosis, effective treatment, and appropriate follow-up. (B recommendation) The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for MDD in children aged 11 years or younger. (I statement).
抗抑郁药物在治疗患有重度抑郁症或者更严重的成人中有很明显的效果(药物反应率为48%-50%,比安慰剂30-32%高出接近20个百分点)。另外也有部分研究发现结合多种抗抑郁药物,或者在早期增大SSRIs用量的话,疗效可能更好。而对于年龄65岁或者更老的患者,药物疗效的反应率与安慰剂的对比差异就没有那么大了。对于年龄小于13岁的小孩,药物和安慰剂的差异很小,并不显著。抑郁症同样对那些患有生理疾病的抑郁患者有效,但是在患有内科疾病(比如高血压,关节炎,肝炎)的患者中疗效较差。对于安慰剂效应,病情越重的抑郁症和忧郁症中安慰剂效应较小,反之,程度较轻,时间较短并且由之前的生活事件所引发的话抑郁症则安慰剂效应较大。当然,有很多研究争论说药物只在病症严重的患者中才有效果,其实并不是这样,虽然药物在程度严重的患者中效果更好,但是在程度较轻的患者中仍然有明显的医疗效果,而且值得注意的是即使不是精神类药物而是我们日常用的药物,它们的安慰剂与药效的对比其实也是相似的数据,只是我们大众和媒体平时过于关注精神类药物才导致我们觉得精神类药物效果差副作用大(这方面我之前的回答链接里有提到)。
×